[go: up one dir, main page]

UA82833C2 - Кристаллическая натриевая соль телмисартана и ее применение в качестве антагониста ангиотензина - Google Patents

Кристаллическая натриевая соль телмисартана и ее применение в качестве антагониста ангиотензина Download PDF

Info

Publication number
UA82833C2
UA82833C2 UA20040503959A UA20040503959A UA82833C2 UA 82833 C2 UA82833 C2 UA 82833C2 UA 20040503959 A UA20040503959 A UA 20040503959A UA 20040503959 A UA20040503959 A UA 20040503959A UA 82833 C2 UA82833 C2 UA 82833C2
Authority
UA
Ukraine
Prior art keywords
telmisartan
sodium salt
formula
acid
crystalline
Prior art date
Application number
UA20040503959A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кай Донсбах
Ірмгард Хоф
Original Assignee
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA82833(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг filed Critical Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг
Publication of UA82833C2 publication Critical patent/UA82833C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке описана кристаллическая натриевая соль 4'-[2-н-пропил-4-метил-6-(1-метилбензимидазол-2-ил)бензимидазол-1-илметил]бифенил-2-карбоновой кислоты (международное непатентованное название телмисартан), способ ее получения, а также ее применения для получения лекарственного средства, которое имеет действие антагониста ангиотензина II.
UA20040503959A 2001-10-31 2002-11-10 Кристаллическая натриевая соль телмисартана и ее применение в качестве антагониста ангиотензина UA82833C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2002/011394 WO2003037876A1 (de) 2001-10-31 2002-10-11 Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist

Publications (1)

Publication Number Publication Date
UA82833C2 true UA82833C2 (ru) 2008-05-26

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040503959A UA82833C2 (ru) 2001-10-31 2002-11-10 Кристаллическая натриевая соль телмисартана и ее применение в качестве антагониста ангиотензина

Country Status (34)

Country Link
EP (1) EP1442023B1 (ru)
JP (1) JP5124076B2 (ru)
KR (1) KR100929502B1 (ru)
CN (1) CN100509789C (ru)
AR (1) AR037148A1 (ru)
AT (1) ATE370125T1 (ru)
AU (1) AU2002338886B2 (ru)
BR (1) BR0213568A (ru)
CA (1) CA2463146C (ru)
CO (1) CO5580785A2 (ru)
CY (1) CY1107504T1 (ru)
DE (2) DE10153737A1 (ru)
DK (1) DK1442023T3 (ru)
EA (1) EA007596B1 (ru)
EC (1) ECSP045089A (ru)
ES (1) ES2291505T3 (ru)
HR (1) HRP20040372A8 (ru)
HU (1) HUP0402391A3 (ru)
IL (2) IL161165A0 (ru)
ME (1) MEP43608A (ru)
MX (1) MXPA04004013A (ru)
MY (1) MY129741A (ru)
NO (1) NO326465B1 (ru)
NZ (1) NZ532716A (ru)
PE (1) PE20030629A1 (ru)
PL (1) PL211462B1 (ru)
PT (1) PT1442023E (ru)
RS (1) RS50879B (ru)
SA (1) SA02230419B1 (ru)
SI (1) SI1442023T1 (ru)
TW (2) TWI333419B (ru)
UA (1) UA82833C2 (ru)
UY (1) UY27520A1 (ru)
WO (1) WO2003037876A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
CN1953973A (zh) * 2004-05-05 2007-04-25 特瓦制药工业有限公司 高纯度坎地沙坦酯的制备
EP1805146A4 (en) 2004-10-18 2009-01-14 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF TELMISARTAN
EP1807400A2 (en) * 2004-11-03 2007-07-18 Teva Pharmaceutical Industries, Inc. Amorphous and polymorphic forms of telmisartan sodium
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
AU2010251194B2 (en) 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
WO2011002425A2 (en) 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CU24354B1 (es) 2011-11-25 2018-08-06 Adverio Pharma Gmbh Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
HRP20240703T1 (hr) 2017-07-07 2024-08-16 Boehringer Ingelheim Vetmedica Gmbh Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka
CN113330013B (zh) * 2019-01-10 2022-12-27 石药集团中奇制药技术（石家庄）有限公司 杂环化合物盐及其应用
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
CN121218995A (zh) 2023-05-24 2025-12-26 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及匹莫苯丹和/或替米沙坦的非人类哺乳动物中心脏疾病的组合治疗和/或预防
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US6174910B1 (en) * 1996-02-29 2001-01-16 Novartis Ag AT1 receptor antagonist for the stimulation of apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
TW200300082A (en) 2003-05-16
AU2002338886B2 (en) 2008-04-17
PT1442023E (pt) 2007-09-17
PL367477A1 (en) 2005-02-21
CA2463146A1 (en) 2003-05-08
IL161165A0 (en) 2004-08-31
CY1107504T1 (el) 2013-03-13
NO326465B1 (no) 2008-12-08
SI1442023T1 (sl) 2007-12-31
DE50210719D1 (de) 2007-09-27
MXPA04004013A (es) 2004-06-18
HRP20040372A2 (en) 2004-10-31
CO5580785A2 (es) 2005-11-30
EP1442023B1 (de) 2007-08-15
SA02230419B1 (ar) 2007-07-31
HRPK20040372B4 (hr) 2025-09-12
MEP43608A (en) 2011-02-10
CN100509789C (zh) 2009-07-08
AR037148A1 (es) 2004-10-27
HUP0402391A3 (en) 2010-03-29
HRP20040372A8 (hr) 2025-09-12
HUP0402391A2 (hu) 2005-03-29
EP1442023A1 (de) 2004-08-04
JP2005536445A (ja) 2005-12-02
KR20050035172A (ko) 2005-04-15
JP5124076B2 (ja) 2013-01-23
CN1578772A (zh) 2005-02-09
EA007596B1 (ru) 2006-12-29
WO2003037876A1 (de) 2003-05-08
HK1073841A1 (en) 2005-10-21
DE10153737A1 (de) 2003-05-28
TWI333419B (en) 2010-11-21
CA2463146C (en) 2011-01-25
BR0213568A (pt) 2004-09-08
RS50879B (sr) 2010-08-31
ATE370125T1 (de) 2007-09-15
TWI341200B (en) 2011-05-01
UY27520A1 (es) 2003-05-30
HRPK20040372B3 (en) 2006-02-28
YU36304A (sh) 2006-08-17
MY129741A (en) 2007-04-30
NZ532716A (en) 2007-06-29
KR100929502B1 (ko) 2009-12-03
TW201034664A (en) 2010-10-01
ECSP045089A (es) 2004-06-28
IL161165A (en) 2009-12-24
NO20041758L (no) 2004-04-29
DK1442023T3 (da) 2007-11-05
EA200400479A1 (ru) 2004-10-28
ES2291505T3 (es) 2008-03-01
PE20030629A1 (es) 2003-07-14
PL211462B1 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
UA82833C2 (ru) Кристаллическая натриевая соль телмисартана и ее применение в качестве антагониста ангиотензина
EP4352056A1 (en) Solid state forms of lanifibranor and process for preparation thereof
EP3022209B1 (en) Dolutegravir potassium salt
US6737432B2 (en) Crystalline form of telmisartan sodium
US20220298117A1 (en) Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
US9029363B2 (en) Telmisartan sodium salt pharmaceutical formulation
RU2198167C2 (ru) Кристаллические модификации 1-(2,6-дифторбензил)-1н-1,2,3-триазол-4-карбоксамида и фармацевтическая композиция
HUP0303928A2 (hu) Omeprazol kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
WO2022217008A1 (en) Solid state forms of zavegepant and process for preparation thereof
SK8312002A3 (en) Novel forms of pravastatin sodium
US20230103724A1 (en) Solid state forms of avapritinib and process for preparation thereof
JP7322151B2 (ja) 医薬化合物、その製造方法、及び薬剤としての使用
US20250042885A1 (en) Solid state forms of lotilaner and process for preparation thereof
US20190152918A1 (en) Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
MXPA05011348A (es) Mesilato de 4-(4-trans -hidroxiciclohexil) amino-2-fenil -7h-pirrolo [2, 3d] pirimidina y sus formas.
WO2025224678A1 (en) Solid state forms of milvexian and process for preparation thereof
WO2007084761A1 (en) Maleate salt of tegaserod and crystalline forms thereof
JP2003530397A (ja) ５−アミノサリチル酸のアゾ誘導体の新規な塩
WO2026003808A1 (en) Solid state form of adagrasib and process for preparation
EP4646406A1 (en) Solid state forms of brilaroxazine and brilaroxazine salts
HK1073841B (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
CA3258700A1 (en) SOLID FORMS OF PALTUSOTINE AND THEIR PREPARATION METHOD
WO2020154581A1 (en) Solid state forms of fedovapagon-salicyclic acid co-crystal
ZA200401780B (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist